World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
123
Citations
62212
World Ranking
3320
National Ranking
91

Overview

Hervé Tilly is affiliated with Grenoble Alpes University in France and has a significant body of research primarily within the field of Medicine. Their scholarly output covers a range of subfields including Pathology and Forensic Medicine, Oncology, Genetics, Pulmonary and Respiratory Medicine, and Cancer Research. The work extends across multiple specialized topics such as Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, Viral-associated cancers and disorders, CNS Lymphoma Diagnosis and Treatment, Cancer Genomics and Diagnostics, and Lung Cancer Treatments and Mutations.

Their research has appeared frequently in notable publication venues, with the highest number of papers published in Blood. Other significant journals of publication include Hematological Oncology, Journal of Clinical Oncology, HemaSphere, and Clinical Lymphoma Myeloma & Leukemia.

Frequent co-authorships feature collaborations with several researchers, including Franck Morschhauser, Olivier Casasnovas, Corinne Haïoun, Catherine Thiéblemont, and Fabrice Jardin. These partnerships reflect ongoing research networks within hematology and oncology.

Among their recent and cited papers are:

  • Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial (2020, The Lancet Oncology)
  • International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI (2020, Blood)
  • High total metabolic tumor volume at baseline predicts survival independent of response to therapy (2020, Blood)
  • Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study (2020, Haematologica)
  • Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study (2024, The Lancet Haematology)

Best Publications

  • CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

    Bertrand Coiffier;Eric Lepage;Josette Briere;Raoul Herbrecht

  • Follicular lymphoma international prognostic index.

    Philippe Solal-Céligny;Pascal Roy;Philippe Colombat;Josephine White

  • Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

    P Feugier;A. Van Hoof;C. Sebban;P. Solal-Celigny

  • Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

    Bertrand Coiffier;Catherine Thieblemont;Eric Van Den Neste;Gérard Lepeu

  • Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study

    B. Coiffier;C. Haioun;N. Ketterer;A. Engert

  • Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

    Gilles Salles;John Francis Seymour;Fritz Offner;Armando Lopez-Guillermo

  • TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

    Cyril Quivoron;Cyril Quivoron;Cyril Quivoron;Lucile Couronné;Lucile Couronné;Lucile Couronné;Véronique Della Valle;Véronique Della Valle;Véronique Della Valle;Cécile K. Lopez;Cécile K. Lopez;Cécile K. Lopez

  • Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    H Tilly;M Gomes da Silva;U Vitolo;A Jack

  • Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte

    P Brice;Y Bastion;E Lepage;N Brousse

  • Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

    Nicolas Mounier;Josette Briere;Christian Gisselbrecht;Jean-Francois Emile

  • Prognostic Significance of T-Cell Phenotype in Aggressive Non-Hodgkin's Lymphomas

    Christian Gisselbrecht;Philippe Gaulard;Eric Lepage;Bertrand Coiffier

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • LAZ3 , a novel zinc–finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas

    Jean-Pierre Kerckaert;Clotilde Deweindt;Hervé Tilly;Sabine Quief

  • Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study

    Corinne Haioun;Eric Lepage;Christian Gisselbrecht;Gilles Salles

  • Treatment of Older Patients with Mantle-Cell Lymphoma

    H. C. Kluin-Nelemans;Eva Hoster;Olivier Hermine;J. Walewski

  • Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.

    Frédéric Peyrade;Fabrice Jardin;Catherine Thieblemont;Antoine Thyss

  • Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

    Franck Morschhauser;John Radford;Achiel Van Hoof;Umberto Vitolo

  • Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

    Karim Belhadj;Felix Reyes;Jean-Pierre Farcet;Herve Tilly

  • An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

    T. E. Witzig;Julie Marie Vose;P. L. Zinzani;C. B. Reeder

  • Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

    Hervé Tilly;Eric Lepage;Bertrand Coiffier;Michel Blanc

Frequent Co-Authors

Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
Corinne Haioun
Corinne Haioun Paris-Est Créteil University
Bertrand Coiffier
Bertrand Coiffier Centre Hospitalier Lyon Sud
Olivier Casasnovas
Olivier Casasnovas Grenoble Alpes University
Philippe Gaulard
Philippe Gaulard Université Paris Cité
Christian Gisselbrecht
Christian Gisselbrecht Université Paris Cité
Thierry Jo Molina
Thierry Jo Molina Université Paris Cité
Olivier Hermine
Olivier Hermine Necker-Enfants Malades Hospital
Christian Recher
Christian Recher Federal University of Toulouse Midi-Pyrénées

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in Medicine but seeking alternative or flexible educational routes, there are several online degrees and career pathways worth exploring. Many students choose nursing as a practical entry point into healthcare, and there are direct entry nursing programs designed for those who hold non-nursing bachelor’s degrees.

Advancing further, candidates without a nursing background can take advantage of direct msn programs online, which offer a fast track to a Master of Science in Nursing through accelerated, flexible coursework.

For those seeking a non-clinical role, online medical billing and coding with financial aid programs provide accessible training in high-demand administrative sectors of healthcare, often with financial support available.

Lastly, prospective nursing students concerned about admissions tests will find nursing schools that don't require teas or hesi can make the path into nursing school less stressful.

These varied online options ensure that aspiring healthcare professionals have multiple flexible routes to begin or advance their medical careers.

Best Scientists Citing Hervé Tilly

Trending Scientists